Targeting Prostate Cancer with a Combination of WNT Inhibitors and a Bi-functional Peptide.

Prostate cancer is the most common cancer in the Western world. A bi-functional peptide was combined with wingless-related integration site (WNT) inhibitors to determine if there is an additive therapeutic effect when they are used against prostate cancer, since their efficacy has already been proven when used alone. A bi-functional peptide (TP-LYT) was designed with a target domain (LTVSPWY) and a lytic domain (KLAKLAK) A synergistic effect of peptides and WNT inhibitors was demonstrated, increasing the toxicity against cancer cells. Our findings potentially allow safer treatment since lower concentrations of WNT inhibitors can be used in combination with this bi-functional peptide.